开云app官网登录入口网页版-官方正版

#非小细胞#

746篇内容 | 5147人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060138, encodeId=724e206013896, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效, objectType=article, longId=738390, objectId=0ba4e3839043, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ba4e3839043, replyNumber=0, likeNumber=97, createdTime=2022-10-07, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ba4e3839043, moduleTitle=辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0ba4e3839043)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060140, encodeId=9a2f2060140c1, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=80, createdTime=2022-09-12, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060119, encodeId=292c2060119be, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, objectType=article, longId=726547, objectId=916ae26547dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=916ae26547dc, replyNumber=0, likeNumber=110, createdTime=2023-03-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=916ae26547dc, moduleTitle=“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=916ae26547dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060117, encodeId=0e3c206011ed1, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, objectType=article, longId=724969, objectId=492be249698c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=492be249698c, replyNumber=0, likeNumber=100, createdTime=2022-08-21, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=492be249698c, moduleTitle=J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=492be249698c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060126, encodeId=e6a62060126c5, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, objectType=article, longId=728264, objectId=993de28264a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=993de28264a3, replyNumber=0, likeNumber=98, createdTime=2023-04-27, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=993de28264a3, moduleTitle=2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=993de28264a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060128, encodeId=d7a1206012877, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=MC：沈阳药科大学团队发现非小细胞肺癌对紫杉醇耐药新机制, objectType=article, longId=728679, objectId=74f3e2867912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f3e2867912, replyNumber=0, likeNumber=109, createdTime=2022-08-03, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f3e2867912, moduleTitle=MC：沈阳药科大学团队发现非小细胞肺癌对紫杉醇耐药新机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74f3e2867912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060122, encodeId=80482060122ff, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, objectType=article, longId=727595, objectId=086be27595c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=086be27595c5, replyNumber=0, likeNumber=99, createdTime=2023-02-02, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=086be27595c5, moduleTitle=J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=086be27595c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060106, encodeId=89bd206010610, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征, objectType=article, longId=302036, objectId=977230203625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=977230203625, replyNumber=0, likeNumber=94, createdTime=2022-04-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=977230203625, moduleTitle=BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=977230203625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060103, encodeId=788f206010309, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=103, createdTime=2022-07-26, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物, objectType=article, longId=724249, objectId=1d43e242498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d43e242498a, replyNumber=0, likeNumber=102, createdTime=2023-01-04, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d43e242498a, moduleTitle=European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1d43e242498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060139, encodeId=68012060139b2, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效, objectType=article, longId=738665, objectId=219ae3866547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=219ae3866547, replyNumber=0, likeNumber=106, createdTime=2023-06-08, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=219ae3866547, moduleTitle=J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=219ae3866547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060112, encodeId=75cd2060112a1, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, objectType=article, longId=723964, objectId=100be239645b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100be239645b, replyNumber=0, likeNumber=96, createdTime=2022-08-07, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100be239645b, moduleTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=100be239645b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060102, encodeId=d7ec20601025e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, objectType=article, longId=301596, objectId=a1cb301596e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1cb301596e2, replyNumber=0, likeNumber=88, createdTime=2022-05-01, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1cb301596e2, moduleTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a1cb301596e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060090, encodeId=4cd82060090e4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=《CSCO非小细胞肺癌诊疗指南2021》更新要点解读, objectType=article, longId=299321, objectId=296929932116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=296929932116, replyNumber=0, likeNumber=85, createdTime=2022-08-11, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=296929932116, moduleTitle=《CSCO非小细胞肺癌诊疗指南2021》更新要点解读, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=296929932116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060109, encodeId=5d18206010903, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, objectType=article, longId=723595, objectId=19f4e2359542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f4e2359542, replyNumber=0, likeNumber=92, createdTime=2022-06-13, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f4e2359542, moduleTitle=BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=19f4e2359542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060095, encodeId=0bd02060095ec, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌, objectType=article, longId=300150, objectId=17e0300150e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17e0300150e7, replyNumber=0, likeNumber=103, createdTime=2022-11-07, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17e0300150e7, moduleTitle=英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=17e0300150e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060132, encodeId=b1df2060132d1, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, objectType=article, longId=731438, objectId=746ae314385a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746ae314385a, replyNumber=0, likeNumber=108, createdTime=2023-03-18, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746ae314385a, moduleTitle=Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=746ae314385a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060130, encodeId=62a62060130ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, objectType=article, longId=729824, objectId=fd9ae2982470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd9ae2982470, replyNumber=0, likeNumber=116, createdTime=2023-05-25, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd9ae2982470, moduleTitle=European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd9ae2982470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060125, encodeId=e50320601256a, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=EClinicalMedicine：一项3期随机、双盲研究表明：MIL60或可作为晚期或复发性非鳞状非小细胞肺癌的替代疗法, objectType=article, longId=728048, objectId=1cb1e28048ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cb1e28048ed, replyNumber=0, likeNumber=102, createdTime=2023-02-13, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cb1e28048ed, moduleTitle=EClinicalMedicine：一项3期随机、双盲研究表明：MIL60或可作为晚期或复发性非鳞状非小细胞肺癌的替代疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1cb1e28048ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060105, encodeId=1734206010580, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=0, createdTime=2022-10-26, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

非小细胞

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

辅助治疗和新辅助治疗加用免疫治疗在可切除性非小细胞肺癌中的疗效

2022-10-07

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2022-09-12

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

“神药”成癌症免疫治疗理想拍档？他汀类或为抗PD-1单药治疗的非小细胞肺癌患者带来生存获益！

2023-03-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Clin Oncol：Durvalumab±Oleclumab/Monalizumab巩固治疗3期非小细胞肺癌的疗效和安全性

2022-08-21

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

2022 ASCO：这些临床特征与晚期非小细胞肺癌患者的功能恢复能力有关

2023-04-27

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

MC：沈阳药科大学团队发现非小细胞肺癌对紫杉醇耐药新机制

2022-08-03

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Thorac Oncol: 国产PD-1抑制剂信迪利单抗新辅助治疗非小细胞肺癌（NSCLC）的三年随访生存结果

2023-02-02

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

BMC Cancer：探索晚期EGFR/ALK突变非小细胞肺癌（NSCLC）生存超5年患者的临床特征

2022-04-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-07-26

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

European Radiology：在非小细胞肺癌患者中，我们又发现了一个强有力的影像学预后标志物

2023-01-04

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Clin Oncol：通用型癌症疫苗在晚期非小细胞肺癌中的免疫原性和疗效

2023-06-08

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究

2022-08-07

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌

2022-05-01

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

《CSCO非小细胞肺癌诊疗指南2021》更新要点解读

2022-08-11

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

BMC Cancer：不可切除III期非小细胞肺癌（NSCLC）铂类放化疗进展后再给予铂类联合化疗可延长生存

2022-06-13

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

英国NICE推荐安进的Lumykras (sotorasib) 治疗非小细胞肺癌

2022-11-07

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Radiology：颅脑MRI对早期非小细胞肺癌患者来说是否多此一举?

2023-03-18

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

European Radiology:微波消融，为无法手术的I期非小细胞肺癌患者带来希望！

2023-05-25

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

EClinicalMedicine：一项3期随机、双盲研究表明：MIL60或可作为晚期或复发性非鳞状非小细胞肺癌的替代疗法

2023-02-13

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-10-26

科室
- - 订阅+
  - 更多科室
工具
服务